Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4575259 | 0.98 | LMNA (0.45) | LMNAKMT2AMEN1TSHRL3MBTL1 | |
| SCHEMBL733288 | 0.80 | LMNA (0.47) | LMNAKMT2AMEN1TSHRL3MBTL1 | |
| SCHEMBL50543 | 0.78 | LMNA (0.46) | LMNAKMT2AMEN1TSHRL3MBTL1 | |
| SCHEMBL4200114 | 0.78 | TSHR (0.46) | LMNAKMT2AMEN1TSHRL3MBTL1 | |
| SCHEMBL304175 | 0.78 | LMNA (0.46) | LMNAKMT2AMEN1TSHRL3MBTL1 | |
| SCHEMBL4616133 | 0.78 | KMT2A (0.49) | LMNAKMT2AMEN1TSHRL3MBTL1 | |
| Hydrochloric Acid SCHEMBL27398725 | 0.77 | LMNA (0.45) | LMNAKMT2AMEN1TSHRL3MBTL1 | |
| SCHEMBL13196349 | 0.77 | LMNA (0.49) | LMNAKMT2AMEN1TSHRL3MBTL1 | |
| SCHEMBL12878853 | 0.75 | TSHR (0.45) | LMNAKMT2AMEN1TSHRL3MBTL1 | |
| SCHEMBL5471173 | 0.75 | LMNA (0.44) | LMNAKMT2AMEN1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1542 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746966-A1 | 4-AMINO-2,6-BIS(PHENYLMETHYLENE)CYCLOHEXANONES AND THEIR USE | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) | 2026-05-27 | — | — | EP | disclosed |
| EP-3704090-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12630548-B2 | Azetidine derivatives for the treatment of integrin associated diseases | THE UNIVERSITY OF NOTTINGHAM (GB) | 2026-05-19 | — | — | US | disclosed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4146651-B1 | SULFONYLAMIDINE SUBSTITUTED COMPOUNDS AND THEIR USE AS BETA-LACTAMASE INHIBITORS | NINGXIA ACADEMY AGRICULTURE & FORESTRY SCIENCES (CN) | 2026-03-04 | — | — | EP | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| WO-1996040686-A1 | HETEROCYCLIC SUBSTITUTED CYCLOPENTANE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996039140-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| EP-0442348-B1 | Imidazole compounds, process for preparation, medicaments based on these compounds and some intermediates | HOECHST AG (DE) | 1996-07-17 | — | — | EP | disclosed |
| CN-1117291-A | 4-Hydroxy-pyran-2-one derivatives for the treatment of retroviral infections | UPJOHN CO (US) | 1996-02-21 | — | — | CN | disclosed |
| EP-0682663-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-22 | — | — | EP | disclosed |
| WO-1995030670-A2 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-16 | — | — | WO | disclosed |
| US-5356922-A | Treatment of disturbances in microcirculation | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-10-18 | — | — | US | disclosed |
| WO-1994018188-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL[B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | THE UPJOHN COMPANY (US) | 1994-08-18 | — | — | WO | disclosed |
| US-5232922-A | Cardiovascular disorders | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-03 | — | — | US | disclosed |
| EP-0442348-A2 | Imidazole compounds, process for preparation, medicaments based on these compounds and some intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | KIF2C, KIF5B, KIF5C | LMNA 560/4885KMT2A 1148/4885MEN1 4063/4885 |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | LMNA 1803/4885KMT2A 2591/4885MEN1 4640/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | LMNA 4258/4885KMT2A 3663/4885MEN1 3901/4885 |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | LMNA 99/4885KMT2A 4742/4885MEN1 4583/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | LMNA 4398/4885KMT2A 1037/4885MEN1 4138/4885 |
| US-12630548-B2 | Azetidine derivatives for the treatment of integrin associated diseases | ITGA2, ITGB2, ITGB1 | LMNA 2493/4885KMT2A 2221/4885MEN1 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.